One To Watch

Neuraxpharm

A European specialty pharmaceutical company focused on central nervous system disorders. The group operates with major hubs in Spain and Germany and maintains a commercial footprint across multiple European markets, supported by a mix of direct affiliates and partner distribution in selected territories.

Founding and History

Neuraxpharm traces its roots to 1985 and has evolved from a CNS-focused portfolio company into a pan-European specialty pharma with a growing branded business. In 2020 the company moved under Permira ownership. Recent years have been characterized by portfolio expansion through acquisitions and in-licensing, alongside balance-sheet activity to support continued growth.

Therapy Areas and Focus

Neuraxpharm is focused on psychiatric and neurological CNS conditions. Core disease areas reflected across its portfolio include epilepsy, multiple sclerosis, Parkinson’s disease, sleep disorders, and mental health indications such as depression and psychosis. The company’s strategy combines established CNS medicines with selected value-added products and newer branded therapies.

Technology Platforms and Modalities

Neuraxpharm is primarily a commercialization and lifecycle-management organization rather than a novel-discovery biotech. Its operating model centers on acquiring, licensing, and scaling CNS medicines across Europe, including generics, value-added formulations, and specialty brands. The company also participates in selected digital health initiatives that complement pharmacotherapy in CNS care.

Key Personnel

Neuraxpharm is led by an executive committee spanning medical, commercial, regulatory, quality, operations, and corporate functions. In 2025, the company appointed Vikas Mohan Sharma as chief medical officer.

Strategic Partnerships

Neuraxpharm positions itself as a European partner of choice for CNS companies seeking regional commercialization. Recent examples include distribution and co-development arrangements, including a Canada distribution agreement for Buccolam and collaborations that combine drug development with device and digital components in CNS indications.

FAQ Section

Neuraxpharm builds CNS franchises by acquiring and licensing products, then scaling them across Europe through established regulatory, market access, and specialty commercial capabilities. The emphasis is on execution in complex CNS markets rather than discovery-stage R&D.

Neuraxpharm focuses exclusively on CNS, spanning neurology and psychiatry. Its portfolio and recent launches highlight epilepsy, multiple sclerosis, Parkinson’s disease, sleep disorders, and selected mental health indications.

The company’s strategy is visible in three levers: maintaining a broad base of CNS molecules, adding differentiated specialty brands, and extending access through lifecycle management and geographic expansion. Recent examples include expansion of its multiple sclerosis offering through the launch of Riulvy and growth in sleep medicine via the acquisition of Provigil and Nuvigil.

Recent disclosed developments include the December 2024 acquisition of Provigil and Nuvigil (announced January 2025), the October 2025 launch of Riulvy in multiple sclerosis, and a November 2025 initiative with mjn-neuro to launch EPISERAS, a wearable-enabled digital health solution for early detection of epileptic seizures. Neuraxpharm also completed a €925 million term-loan refinancing reported in August 2025.

As a specialty pharma and commercialization company, Neuraxpharm more often communicates real-world positioning, lifecycle strategy, and label-driven evidence for marketed products rather than sponsoring large pivotal programs itself. When it highlights clinical evidence, it is typically tied to products it markets or partners on, such as long-term datasets presented for its MS franchise.

Milestones are typically product launches, geographic expansions, and new in-licensing or acquisition activity. Near-term focus areas generally include expanding the reach of newer CNS brands, adding differentiated assets in priority franchises such as multiple sclerosis and epilepsy, and executing digital or device-adjacent programs where they strengthen clinical pathways.

Neuraxpharm is run by a senior leadership team structured around CNS medical and commercial execution, with dedicated functions for regulatory, pharmacovigilance, quality, supply, and business development to support multi-country European operations and ongoing portfolio expansion.

Want to Update your Company's Profile?